Sign up
Pharma Capital

Liberty Health Sciences signs deal to use AI-driven analytics to boost cannabis production

Adaviv will use plant biometrics to provide insights to Liberty on its cannabis production
Cannabis in a greenhouse.
Liberty Health Sciences is a cannabis producer based in Toronto

Liberty Health Sciences (CSE:LHS) (OTCQX:LHSIF) said on Thursday they have signed an exclusive partnership with AdaViv Inc to improve production of cannabis at its Liberty Health Sciences (LHSIF) facility in Gainesville, Florida. 

AdaViv will integrate its adaptive Computer Vision software and Machine Learning platform into Liberty's 360 Innovation Campus and, together, they will look to push the state-of-the-art in greenhouse technology and precision growing to new levels of productivity and efficiency, a company statement said.

AdaViv's technology enables constant plant-level inspection while the AI computer can uncover hidden plant biometrics that translates data into actionable insights for growers like Liberty.

"We take cultivation seriously and through the implementation of AdaViv we will have the necessary information to greatly improve our cultivation output," said George Scorsis, the chief executive of Liberty Health Sciences.

READ: Liberty Health Sciences takes a step into Florida’s vaporizer market

Liberty operates four dispensaries and six delivery hubs. The company has also signed seven new leases for dispensaries that are at various stages of construction.

Last week, the company reported a 95% increase in sales revenue in the three-month period ended August 31, 2018, compared to the previous three-month period that ended May 31, 2018.

Liberty also reported a 112% increase of almost 10,000 patients being seen at the company's dispensaries at the end of August, up from 4,600 by the end of last May.

Shares of the company in the over-the-counter market in New York were trading at US$0.97, down 2.5% for the day.

Liberty Health Sciences is a cannabis producer. The company is based in Toronto, Canada.

 



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.